Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells

NCT00004036 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT00004036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells
Lead sponsor
The Cleveland Clinic
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 1997
Completion date
Not reported
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, drug/agent toxicity by tissue/organ, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, precancerous condition, unspecified adult solid tumor, protocol specific